Retaane® in Age-Related Macular Degeneration

Status

Completed

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00569569

Enrollment

Registered

2007-12-07

Start date

2006-02-28

Completion date

2007-03-31

Last updated

2007-12-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Age Related Macular Degeneration

Brief summary

The treatment of fibrotic choroidal neovascular lesions with presence of residual peripheral activity in age related macular degeneration currently presents a great challenge. With visual loss threatening, there are only very few therapeutic options. While these patients are neither suitable for laser therapy nor for photodynamic therapy with Verteporfin, antiangiogenic drugs applied intravitreally are now available. Some patients however reject this therapeutic option because of potential complications such as endophthalmitis and the frequency of necessary injections. 20 patients who rejected intravitreal therapy were treated with Anecortave acetate (Retaane®) which was applied as a juxtascleral depot injection.

Interventions

DRUGjuxtascleral depot injection of Retaane

juxtascleral depot injection of Retaane

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

20 Years to 90 Years

Healthy volunteers

Inclusion criteria

* rejection of intravitreal injections * presence of fibrotic choroidal neovascular lesions with presence of residual peripheral activity in age related macular degeneration

Exclusion criteria

* conditions precluding judgement of the fundus

Design outcomes

Primary

Measure	Time frame
Increase in VA	6 months

Secondary

Measure	Time frame
Decrease in Macula Edema	6 months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026